Organoids are tissue analogues with defined spatial structures generated by three-dimensional in vitro culture of adult stem cells or pluripotent stem cells. They highly recapitulate the tissue architecture, cell types, self-renewal capacity and biological functions of their source tissues. Therefore, organoids possess unique advantages across diverse biomedical fields, including developmental biology, disease modeling, precision medicine, drug discovery, gene and cell therapy, infection and immunity, as well as regenerative medicine.
Product Description SB202190 is a selective p38 MAP kinase inhibitor, with IC50 values of 50 nM and 100 nM against p38α and p38β2, respectively. SB202190 binds to the ATP pocket of active recombinant human p38 kinase with a Kd of 38 nM. It exhibits anti-cancer activity, rescues memory deficits and triggers autophagy.
BIOLOGICAL ACTIVITY In Vitro SB202190 (0–10 μM; 0–72 h) suppresses the growth of a subset of CRC cell lines including RKO, CACO2 and SW480 in a dose‑ and time‑dependent manner. At 10 μM for 7–10 days, SB202190 markedly suppresses colony formation and anchorage‑independent growth; treatment for 72 h (10 μM) increases apoptotic cell death in these CRC cell lines (RKO, CACO2 and SW480). In RKO, CACO2 and SW480 cells, SB202190 (10 μM; 2 h) abolishes phosphorylation of S6K1(T389) and S6(S235/236), while AKT(S473) phosphorylation remains unaffected. This demonstrates that p38 inhibition selectively blocks mTORC1 signaling.
In Vivo SB202190 (5 mg/kg, intraperitoneal injection, daily for 10–12 days) inhibits tumor cell survival and tumor growth.

